



## Universal Treatment Considerations

Consider universal needs of people using stimulant to promote wellness including:

- Overamping prevention
- Opioid overdose prevention/education
- Naloxone distribution
- “Chill packs”
- HIV treatment/prevention (PrEP, nPEP, TasP)

(Centers for Disease Control and Prevention, 2022; Coffin, 2024; National Harm Reduction Coalition, 2020; Substance Abuse and Mental Health Services Administration, 2021)

28

---

---

---

---

---

---

---

---

---


---

## Medications to Treat CUD

There are no FDA-approved medications to treat CUD, but there are several medications with trials with promising results including:

- Topiramate +/- MAS-ER
- Long-acting stimulants
- Topiramate
- Bupropion

The use of medications to treat CUD should be considered by clinicians with experience caring for individuals with addiction.



(Carpenter et al., 2024; Chan et al., 2019; Johnson et al., 2013; Levin et al., 2015, 2020; Pani et al., 2011; Prince & Bowling, 2018; Siniscalchi et al., 2015)

29

---

---

---

---

---

---

---

---

---


---

## Medications to Treat MUD

There are no FDA-approved medications to treat MUD, but there are several medications with trials with promising results including:

- Bupropion +/- Naltrexone-ER
- Mirtazapine
- Long-acting injectable antipsychotics
- Bupropion
- Long-acting stimulants

The use of medications to treat MUD should be considered by clinicians with experience caring for individuals with addiction.



(Bakouni et al., 2023; Chamakalayil et al., 2021; Coffin et al., 2020; Ezard et al., 2021; Heikkinen et al., 2023; Kidd et al., 2023; Najj et al., 2022; Noroozi et al., 2020; Sadegh et al., 2023; Tardelli et al., 2020; Trivedi et al., 2021; Wang et al., 2020)

30

---

---

---

---

---

---

---


---

---

---

**Behavioral Health Interventions**

- ❖ Strength-based behavioral health interventions have the strongest evidence for the treatment of stimulant use disorders.
- ❖ Contingency management (CM) with high-fidelity to standardized protocols is highly effective in treating StUD.
- ❖ CM is a therapeutic intervention that uses principles of behavioral analysis to promote neurological changes and improved recovery outcomes.

 (Pfund et al., 2021; Rash, 2023; Rash et al., 2020)

31

---

---

---

---

---


---

---

---

**Behavioral Health Interventions**

- ❖ Additional therapeutic modalities with evidence for the treatment of StUD include:
  - Cognitive behavioral therapy (CBT)
  - Motivational interviewing (MI)
  - Community Reinforcement Approach (CRA)
  - Matrix model
  - Exercise-supported recovery

 (AshaRani et al., 2020; Carroll & Kiluk, 2017; Marrero-Cristobal et al., 2022; Substance Abuse and Mental Health Services Administration, 2021)

32

---

---

---

---

---


---

---

---

**Take Home Points**

- ❖ The number of people using stimulants and experiencing stimulant use disorders is rising in the United States.
- ❖ There are available behavioral health treatment interventions that are highly effective to treat people with StUDs.
- ❖ There is a growing body of evidence to support the use of medications in treating StUD.
- ❖ People with stimulant use disorders can and do experience recovery.

 33

33

---

---

---

---

---

---

---

---

# References

Alcohol and Drug Foundation (2020, March 7). Stimulants—Alcohol and Drug Foundation. <https://adfd.org.au/long-term-issues/>

Alon, J., Bock, V., Bekdash, H., Pabiani, L., Claudio, A., Bock, M., Labella, C. T., & Ventura, A. S. (2020). Starting the Discussion: A Call to Enhance Care for People With Stimulant Disorder. *Substance Abuse*, 41(5), 519–524. <https://doi.org/10.1080/08897064.2020.1811111>

Ashkanani, P., Hordahl, A., Sosa, E., Ong, W. A., Tan, J. H., & Subramaniam, M. (2020). Non-pharmacological interventions for methamphetamine use disorder: A systematic review. *Drug and Alcohol Dependence*, 212, 108190. <https://doi.org/10.1016/j.drugalcdep.2020.108190>

Avram, C. A., & Janda, R. (2010). Methamphetamine: Spectacle of crystal meth: A media created mythology? *Crime, Media, Culture International Journal*, 8(5), 325–332. <https://doi.org/10.1177/1741274110384411>

Bakken, H., Sharabi, R., Behremani, A., Dinos, S., Dinger, S., Bock, P., La-Pol, B., Shihata, C. G., Terrell, V., Ewald, M., Safford, M., & Janda, A. M. D. (2021). Bupropion for treatment of amphetamine type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. *Drug and Alcohol Dependence*, 213, 108206. <https://doi.org/10.1016/j.drugalcdep.2021.108206>

Carperker, M., Choi, C. J., Bawarika, C., Pauloska, M., Brooks, D. J., Brasing, C. A., Shiga, A., Naran, V. V., Mariani, J. J., & Levin, F. R. (2014). Mixed amphetamine salts extended-release (MMS ER) as a behavioral treatment augmentation strategy for cocaine use disorder: A randomized clinical trial. *Experimental and Clinical Psychopharmacology*, 32(1), 112–127. <https://doi.org/10.1037/xcp0000016>

Carroll, K. M., & Nuro, K. B. (2017). Cognitive behavioral interventions for alcohol and drug use disorders: Through the etiological and back again. *Psychology of Addictive Behaviors*, 73(1), 841–861. <https://doi.org/10.1016/j.ychbeh.2017.07.004>

Centers for Disease Control and Prevention. (2022). *A Stimulant Guide: Answer to Emerging Questions about Stimulants in the Context of the Opioid Epidemic in the United States*. U.S. Department of Health and Human Services. <https://www.cdc.gov/odasat/2022/08/22/2022-08-22-stimulant-guide.pdf>

Chen, H., & Wang, S. (2021). Methamphetamine for Attention-Deficit and Hyperactivity Disorder in Adult Patients With Substance Use Disorders: Good Clinical Practice. *Frontiers in Psychiatry*, 11, 584267. <https://doi.org/10.3389/fpsyt.2021.584267>

Chen, A., Naranjo, A., Freeman, W., Agnes, C., Montgomerie, J., & Kavanagh, D. (2019). Pharmacotherapy for Cocaine Use Disorder—A Systematic Review and Meta-analysis. *Journal of General Internal Medicine*, 34(12), 2282–2291. <https://doi.org/10.1007/s11622-019-0924-8>

Coffin, P. G. (2014). Evaluation of methamphetamine analgesic as needed antipsychotics for self-management of methamphetamine-associated psychiatric toxicity. *International Journal of Drug Policy*, 35(1), 20–25. <https://doi.org/10.1016/j.drugpo.2013.09.001>

Coffin, P. G., Santos, G. W., Hays, J., Winstanley, E., Walker, J. E., Mahabadi, T., Santos, D., Coffin, G., & Boffa, L. J. (2020). Effects of Mirtazapine for Methamphetamine Use Disorder Among Opioid-Use and Nonopioid-Use Women With and Without a History of Cocaine Use. *Drug and Alcohol Dependence*, 204, 107978. <https://doi.org/10.1016/j.drugalcdep.2019.107978>

David, N., Robinson, B., Dooling, A., Brown, R., Carr, A., Liu, Z., Safford, M., & L. Higgins, N. (2021). Safety and tolerability of oral bupropion in adults with methamphetamine dependence: A placebo-controlled randomised trial. *Journal of Clinical Pharmacy and Therapeutics*, 46(1), 105–114. <https://doi.org/10.1111/jcpt.12400>

Freeman, J., & Sosa, E. (2021). Changing the Narrative: Geographic, temporal, race/ethnicity, and demographic trends in polysubstance (heroin) overdose deaths in the United States, 2005–2015. *Addiction*, 116(10), 2477–2487. <https://doi.org/10.1111/add.14833>

Han, B., Coffin, P., Do, M., Omboni, S., Compton, W. M., & Volkow, N. D. (2021). Methamphetamine Overdose Deaths in the US by Sex and Race and Ethnicity. *JAMA Psychiatry*, 78(5), 554. <https://doi.org/10.1001/jamapsychiatry.2021.0144>

34

# References

Hickson, M., Tappin, H., Tanskanen, A., Mikkilineni, R., E., Lyhanen, M., & Tiihonen, J. (2020). Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Psychotic Disorder in a Finnish Nationwide Cohort of 10,563 Patients. *JAMA Psychiatry*, 77(11), 1111–1120. <https://doi.org/10.1001/jamapsychiatry.2020.2122>

Johnson, B. A., Ah Doud, N., Wang, X., Q. Pendergast, J., Kim, H. A., Serranero, C., & Liu, L. (2013). Topiramate for Treatment of Cocaine Addiction: A Randomized Clinical Trial. *JAMA Psychiatry*, 70(12), 1318. <https://doi.org/10.1093/ajph.2013.03.014>

Kidd, J. D., Smiley, S. J., Coffin, P. G., Carrozzini, T. J., Lewis, F. B., Hayes, E. V., Dooling, S. J., & Trowell, M. H. (2018). Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder. *Drug and Alcohol Dependence*, 185, 114–120. <https://doi.org/10.1016/j.drugalcdep.2018.03.004>

Levin, F. R., Mariani, J. J., Pauloska, M., Choi, C. J., Mahabadi, T., Brooks, D. J., Shiga, A., Carperker, M., Naran, V. V., & Freeman, W. (2020). Extended-release mixed amphetamine salts for treatment of cocaine dependence: A randomized clinical trial in patients with heroin use. *Drug and Alcohol Dependence*, 204, 107978. <https://doi.org/10.1016/j.drugalcdep.2019.107978>

Levin, F. R., Mariani, J. J., Carperker, M., Naran, V. V., Brooks, D. J., Shiga, A., Choi, C. J., Naran, V. V., & Carperker, M. (2019). Extended-release mixed amphetamine salts for treatment of Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*, 76(5), 593. <https://doi.org/10.1093/ajph.2018.08.011>

Li, M., & Sheehan, S. J. (2022). Clinical management of psychostimulant withdrawal: Review of the evidence. *Addiction*, 117(6), 705–714. <https://doi.org/10.1111/add.14800>

Martinez-Cristobal, G., Gallo-Dominguez, M., Morales-Silva, R., Alvarado-Torres, J., Perez-Torres, J., Perez-Perez, T., & Sepulveda-Orrigoien, M. (2022). Aerobic exercise as a promising nonpharmacological therapy for the treatment of substance use disorders. *Journal of Ethnopharmacology Research*, 13(6), 3402–3407. <https://doi.org/10.1002/etp.4486>

Naji, L., Dennis, B., Rossi, T., Wiercicki, W., Paul, J., Winkler, A., Thushian, L., & Samaan, Z. (2022). Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysis. *Drug and Alcohol Dependence*, 222, 109195. <https://doi.org/10.1016/j.drugalcdep.2021.109195>

National Harm Reduction Coalition. (2020a, August 10). *Emerging Stimulant Overlapping: National Harm Reduction Coalition*. <https://harmreduction.org/newsroom/newsroom-items/national-harm-reduction-coalition>

National Harm Reduction Coalition. (2020b, October 15). *Safe! Drug Use 101: Harm Reduction Coalition*. <https://harmreduction.org/newsroom/what-we-do/safe!-drug-use-101>

Nemoto, A., Matsuda, A., A., Zammit, M. B., Alghamdi, R., J., & Alford, A. S. (2022). Adding extended-release methylphenidate to psychological intervention for treatment of methamphetamine dependence: A double-blind, randomised controlled trial. *Journal of Clinical Pharmacy and Therapeutics*, 47(1), 101–110. <https://doi.org/10.1111/jcpt.12400>

Pearl, D. P., Teng, Y., Wirths, S., & Bostan, L. (2012). Interventions for cocaine dependence and problematic cocaine use. *Cochrane Database of Systematic Reviews*, 12. <https://doi.org/10.1002/14651402.cd009704>

Pauloska, M. P., & Stewart, J. L. (2020). Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder. *JAMA Psychiatry*, 77(9), 955. <https://doi.org/10.1001/jamapsychiatry.2020.2122>

Plourd, B. A., Griley, M. K., Rauh, C. J., & Zujewski, K. (2021). Contingency management for treatment attendance: A meta-analysis. *Journal of Substance Abuse Treatment*, 128(56).

Pollock, M. M., Green, E. R., Horton, S. J., Ludman, N. J., & Moore, P. H. (2020). Medical, Neurological, and Legal Stimulant Use by Sexual Identity and Gender. *American Journal of Preventive Medicine*, 55(5), 686–690. <https://doi.org/10.1016/j.amepre.2020.07.001>

35

# References

Primm, V., & Bowling, K. C. (2010). Topiramate in the treatment of cocaine use disorder. *American Journal of Health-System Pharmacy*, 67(3), 413–422. <https://doi.org/10.2195/ajhp.2010.67.3.413>

Rauh, C. J. (2022). Implementing evidence-based contingency management protocol for stimulant use. *Journal of Substance Use and Addiction Treatment*, 1(1), 000179. <https://doi.org/10.1002/jsuat.100179>

Rauh, C. J., Allen, S. M., & Zujewski, K. (2022). EXAMINING IMPLEMENTATION OF CONTINGENCY MANAGEMENT IN REAL-WORLD SETTINGS. *Psychology of Addictive Behaviors*. *Journal of the Society for Psychological and Addictive Behaviors*, 124, 103198. <https://doi.org/10.1016/j.ychbeh.2022.103198>

Salegh, A. B., Nazarian, M., Dehghanian, T., Rostami, R., & Mehrabi, M. (2022). The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial. *Iranian Journal of Psychiatry*. <https://doi.org/10.30473/ijps.2022.103198>

Srinivas, H., Bani, A. K., Mariani, J. B., Freeman, D., Safford, A., Ferris, C. D., & Galanter, L. (2013). The Role of Topiramate in the Management of Cocaine Addicts: A Flexible Therapeutic Option. *Current Neuropharmacology*, 12(6), 815–823. <https://doi.org/10.2165/000030110130001206008>

Substance Abuse and Mental Health Services Administration. (2021). *Treatment for Stimulant Use Disorders: Treatment Improvement Protocol (TIP) Series 321* (SAMHSA Publication No. PE21-01-01-006).

Tang, S., Jones, C. M., Whitson, A., Liu, V. C., Dixon, S., & Huxley, D. (2021). Adverse childhood experiences and stimulant use disorders among adults in the United States. *Psychiatry Research*, 295, 113870. <https://doi.org/10.1016/j.psychres.2021.113870>

Terrell, V. S., Shiga, A., Kiradegem, B., Carr, C., Levin, F. R., & Pridgen, T. M. (2020). Prescription psychostimulants for the treatment of stimulant use disorder: A systematic review and meta-analysis. *Psychopharmacology*, 237(1), 223–235. <https://doi.org/10.1007/s00127-020-01844-4>

Trank, M. R., Green, T. L., Safford, M., Campbell, C., Carperker, M., Walker, B., Winkler, A., Stone-Williams, B., Dooling, M., Omboni, S., Robinson, H., Higgins, C., Lewis, L., Samaan, Z., Jones, A., Coffin, P., & Levin, F. R. (2021). Randomized Controlled Trial Comparing Extended-Release Methylphenidate to Psychological Interventions for Stimulant Use Disorder: Results From the CTR-007 Treatment Research Network. *Drug Dependence*, 179(10), 102759. <https://doi.org/10.1016/j.drugdep.2021.102759>

Trank, M. R., Walker, R., Ling, W., Winkler, A., Kim, M., Stone-Williams, B., Safford, M., Coffin, P., Schmitz, J., Winkler, A., Bani, A. K., Sosa, E. V., & Safford, M. (2021). Bupropion and Naltrexone in Methamphetamine Use Disorder. *NIJ Drug Med*, 14.

Wang, G., Ding, T., Chavakis, H. C., Jiao, W., Liu, X., Ding, Q., & Ouyang, X. (2020). Randomized Controlled Trial of Paliperidone Extended-Release Versus Trifluoperazine for the Treatment of Methamphetamine-Associated Psychotic Disorder. *Frontiers in Psychiatry*, 11, 584267. <https://doi.org/10.3389/fpsyt.2020.584267>

Wood, S., Sagar, R., Shuman, T., & Kogut, S. G. (2014). Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation. *Pharmacological Reviews*, 66(1), 103–121. <https://doi.org/10.1124/pr.113.000000>

36